Resultados de la búsqueda 1311-1320 of 4302 for AM - PM
... are safe for people to take. We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab ...
Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without ...
This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies. Developing a way to track ...
Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in ...
... p.m. CDT; New study finds triple-negative breast cancer tumors with an ... 04, 2023, 11:00 a.m. CDT; Beyond BRCA1/2: Pinpointing the risk of inherited breast ...
... p.m. CDT; Mayo Clinic surgeon: Living kidney ... a.m. CDT; Mayo Clinic Minute: What is a living ... p.m. CDT; Transforming Transplant Initiative aspires ...
... p.m. CDT; 5 things to know about stroke May 04, 2024, 11:00 a.m. CDT; Mayo Clinic Minute: Preventing stroke May 02, 2024, 05:00 p.m. CDT; Mayo Clinic Minute ...
Breast cancer patients are more than three times at risk for developing congestive heart failure (CHF), compared with patients who did not have cancer. The ...
Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?